Emerging strategies for the treatment of gastroparesis

References

• Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37.
   PubMed Web of Science ®Google Scholar
• Soykan I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–2404.
   PubMed Web of Science ®Google Scholar
• Parkman H. Idiopathic Gastroparesis. Gastroenterol Clin N Am. 2015;44:59–68.
   PubMed Web of Science ®Google Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11–19.
   PubMed Web of Science ®Google Scholar
• Nguyen LA, Snape WJ Jr. Clinical presentation and pathophysiology of gastroparesis. Gastroenterol Clin N Am. 2015;44:21–30.
   PubMed Web of Science ®Google Scholar
• Singh SP, et al. Nausea: a review of pathophysiology and therapeutics. Ther Adv Gastroenterol. 2016;9(1):98–112.
   PubMed Web of Science ®Google Scholar
• Pasricha P, Parkman H. Gastroparesis definitions and diagnosis. Gastroenterol Clin N Am. 2015;44:1–7.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M. Prokinetics in Gastroparesis. Gastroenterol Clin North Am. 2015;44(1):97–111.
   PubMed Web of Science ®Google Scholar
• McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–467.
   PubMed Web of Science ®Google Scholar
• Snape WJ Jr, Battle WM, Schwartz SS, et al. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96(4):444–446.
   PubMed Web of Science ®Google Scholar
• Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379–390.
   PubMed Web of Science ®Google Scholar
• Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010;5(5):653–662.
   PubMedGoogle Scholar
• Parkman HP, Mishra A, Jacobs M, et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46(6):494–503.
   PubMed Web of Science ®Google Scholar
• Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide- induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153(12):1469–1475.
   PubMedGoogle Scholar
• Van Nueten JM, Ennis C, Helsen L, et al. Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone. Life Sci. 1978;23(5):453–457.
   PubMed Web of Science ®Google Scholar
• Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther. 1998;20(3):438–453.
   PubMed Web of Science ®Google Scholar
• Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84(9):1069–1075.
   PubMed Web of Science ®Google Scholar
• Schuurkes JA, Van Nueten JM. Domperidone improves myogenically transmitted antroduodenal coordination by blocking dopaminergic receptor sites. Scand J Gastroenterol Suppl. 1984;96:101–110.
   PubMedGoogle Scholar
• Sol P, Pelet B, Guignard JP. Extrapyramidal reactions due to domperidone. Lancet. 1980;2:802.
   Google Scholar
• Franckx J, Noel P. Acute extrapyramidal dysfunction after domperidone administration. Report of a case. Helv Paediatr Acta. 1984;39:285–288.
   PubMedGoogle Scholar
• Debontridder O. Dystonic reactions after domperidone. Lancet. 1980;2:1259.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Jacobs MR, Mishra A, et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci. 2011;56(1):115–124.
   PubMed Web of Science ®Google Scholar
• Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary Studies. N Engl J Med. 1990;322(15):1028–1031.
   PubMed Web of Science ®Google Scholar
• Coulie B, Tack J, Peeters T, et al. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut. 1998;43:395 400.
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–1096.
   PubMed Web of Science ®Google Scholar
• Weber FH Jr, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol. 1993;88(4):485–490.
   PubMed Web of Science ®Google Scholar
• Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88:203–207.
   PubMed Web of Science ®Google Scholar
• Leming S, Broad J, Cozens SJ, et al. GSK962040: a small molecule motilin re- ceptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil. 2011;23(10):958–958.e410.
   PubMed Web of Science ®Google Scholar
• Broad J, Mukherjee S, Samadi M, et al. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol. 2012;167(4):763–774.
   PubMed Web of Science ®Google Scholar
• Barshop K, Kuo B. The investigational drug camicanal for the treatment of gastroparesis. Expert Opin Investig Drugs. 2015;24(1):133–140.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Tesu C, Sudo M. Effect of RQ-00201894, a small non-peptide motilin agonist, on laparotomy and clonidine induced gastrointestinal hypomotility in dogs. Dig Dis Week Abstract. 2013.
   Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes AJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterology Motility. 2008;20:99–112.
   PubMed Web of Science ®Google Scholar
• Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2010;19(6):765–775.
   PubMed Web of Science ®Google Scholar
• Bouras E, Camilleri M, Burton D, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354–360.
   PubMed Web of Science ®Google Scholar
• Shin A, Acosta A, Camilleri M, et al. A randomized trial of 5-Hydroxytryptamine 4- receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015;13(4):701–708.e1. doi:10.1016/j.cgh.2014.08.012
   Web of Science ®Google Scholar
• Kressing BF, Smout AJPM, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterology Motil. 2014;26(8):1079–1086. doi:10.1111/nmo.12359
   Web of Science ®Google Scholar
• James AN, Ryan JP, Crowell MD, et al. Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G612–9.
   Google Scholar
• Cellini J, DiNovo K, Harlow J, et al. Regional differences in neostigmine-induced contraction and relaxation of stomach from diabetic guinea pig. Auton Neurosci. 2011;160:69–81.
   PubMed Web of Science ®Google Scholar
• Lucey MA, Patil V, Girling K, et al. Does neostigmine increase gastric emptying in the critically ill?–results of a pilot study. Crit Care Resusc. 2003;5(1):14–19.
   PubMedGoogle Scholar
• Nowlan ML, Scott LJ. Acotiamide: a first global approval. Drugs. 2013;73(12):1377–1383.
   PubMed Web of Science ®Google Scholar
• McCallum R. Status of pharmacologic management of gastroparesis: 2014. Gastrointestinal motility and functional bowel disorders, series #1. Pract Gastroenterol. 2014.
   Google Scholar
• Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2009;6(6):343–352.
   PubMed Web of Science ®Google Scholar
• Venkova K, Greenwood-Van Meerveld B. Application of ghrelin to gastrointestinal diseases. Curr Opin Investig Drugs. 2008;9:1103–1107.
   PubMedGoogle Scholar
• Lasseter KC, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2008;48:193–202. [PubMed: 18199894]
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28- day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013;25(2):e140–50.
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clin Gastroenterol Hepatol. 2013;11(11):1453–1459.
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M, McCallum R, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology. 2014;146(Suppl 1):S158–9.
   Google Scholar
• Dudekula A, et al.Time trends in gastroparesis treatment. Dig Dis Sci. 2014;59(11):2656–2665. Epub 2014 Sep 26. doi:10.1007/s10620-014-3369-y
   PubMed Web of Science ®Google Scholar
• Samsom M, Salet GA, Roelofs JM, et al. Compliance of the proximal stomach and dyspeptic symptoms in patients with type I diabetes mellitus. Dig Dis Sci. 1995;40:2037–2042.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha A, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2011;9(1):5–e7.
   PubMed Web of Science ®Google Scholar
• Barrett TW, DiPersio DM, Jenkins CA, et al. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am J Emerg Med. 2011;29:247–255.
   PubMed Web of Science ®Google Scholar
• Owczuk R, Twardowski P, Dylczyk-Sommer A, et al. Influence of promethazine on cardiac repolarisation: a double-blind, midazolam-controlled study. Anaesthesia. 2009;64:609–614.
   PubMed Web of Science ®Google Scholar
• Grissinger M. Preventing serious tissue injury with intravenous promethazine. Pharm Ther. 2009;34(4):175–176.
   Google Scholar
• Browning K. Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Front Neurosci. 2015;9:413.
   PubMedGoogle Scholar
• Rojas C, Raje M, Tsukamoto T, et al. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol. 2014;722:26–37.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Hvid-Jacobsen K, Lund P, et al. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion. 1990;46(2):89–96.
   PubMed Web of Science ®Google Scholar
• Simmons K, Parkman HP. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig Dis Sci. 2014;59(6):1231–1234. doi:10.1007/s10620-014-3097-3.
   PubMed Web of Science ®Google Scholar
• Hejazi RA, Reddymasu SC, Namin F, et al. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol. 2010;44(1):18–21.
   PubMed Web of Science ®Google Scholar
• Sawhney M, Prakash C, Lustman P, et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2007;52(2):418–424.
   PubMed Web of Science ®Google Scholar
• Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. Jama. 2013;310:2640–2649.
   PubMed Web of Science ®Google Scholar
• Gooden JY, Takahashi P. Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual: a case report. J Med Case Rep. 2013;7:38.
   PubMedGoogle Scholar
• Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics. 2006;47:440–442.
   PubMed Web of Science ®Google Scholar
• Yin J, Song J, Lei Y, et al. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol. 2014;306(9):G796–801.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112–4119.
   PubMed Web of Science ®Google Scholar
• Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother. 2012;46(12):e38.
   PubMedGoogle Scholar
• Chong K, Dhatariya K. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. Nat Rev Endocrinol. 2009;5(5):285–288.
   PubMed Web of Science ®Google Scholar
• Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533–543.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Eckert D, et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 2012;24:358–e169.
   PubMed Web of Science ®Google Scholar
• Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53:1566–1570.
   PubMed Web of Science ®Google Scholar
• Pasricha P. Future directions in the treatment of gastroparesis. Gastroenterol Clin N Am. 2015;44:185–189.
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liu HT, Yang WC. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol. 2006;176:641–645.
   PubMed Web of Science ®Google Scholar
• Hawari R, Yin J, Sallam H, et al. Topical intragastric application of the TRPV1 agonist, resiniferatoxin (RTX), attenuates experimental nausea and vomiting. Gastroenterology. 2007;132:A–688.
   Google Scholar
• Evans AT, Samuels S, Marshall C, et al. Suppression of pregnancy-induced nausea and vomiting with sensory afferent stimulation. J Reprod Med. 1993;38(8):603–606.
   PubMed Web of Science ®Google Scholar
• Dundee JW, Yang J, McMillan C. Non-invasive stimulation of the P6 (Neiguan) antiemetic acupuncture point in cancer chemotherapy. J R Soc Med. 1991;84:210–212.
   PubMed Web of Science ®Google Scholar
• Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med. 2004;24:163–165.
   PubMedGoogle Scholar
• Wang CP, Kao CH, Chen WK, et al. A single-blinded, randomized pilot study evaluating effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis. J Altern Complement Med. 2008;14:833–839.
   PubMed Web of Science ®Google Scholar
• Chen J, Sarosiek I, McCallum R, et al. Chronic transcutaneous electroacupuncture ameliorates dyspeptic symptoms in patients with diabetic gastroparesis: a placebo-controlled multicenter clinical trial using a newly developed microstimulator. Abstract. South Regional Meet. 2013.
   Google Scholar
• Sharma VK, Glassman SB, Howden CW, et al. Pyloric intrasphincteric botulinum toxin (Botox) improved symptoms and gastric emptying in a patient with diabetic gastroparesis (abstr). Am J Gastroenterol. 1998;93:456.
   Google Scholar
• Lacy BE, Schettler-Duncan VA, Crowell MD. The treatment of diabetic gastroparesis with botulinum toxin (abstr). Am J Gastroenterol. 2000;95:2455–2456.
   Google Scholar
• Muddasani P, Ismail-Beigi F. Diabetic gastroparesis a possible new indication for botulinum toxin injection (abstr). Am J Gastroenterol. 2001;97:S255.
   Google Scholar
• Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol. 2002;97:1653–1660.
   PubMed Web of Science ®Google Scholar
• Bromer MQ, Friedenberg F, Miller LS, et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61:833–839.
   PubMed Web of Science ®Google Scholar
• Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26:1251–1258.
   PubMed Web of Science ®Google Scholar
• Friedenberg FK, Palit A, Parkman HP, et al. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103:416–423.
   PubMed Web of Science ®Google Scholar
• Ukleja A, Tandon K, Shah K, et al. Endoscopic botox injections in therapy of refractory gastroparesis. World J Gastrointest Endosc. 2015;7(8):790–798.
   PubMed Web of Science ®Google Scholar
• Lacy BE, et al. The treatment of diabetic gastroparesis with botulinum toxin injections of the pylorus. Diabetes Care. 2004;27:2341–2347.
   PubMed Web of Science ®Google Scholar
• Mancini S, Angelo J, Peckler Z, et al. Pyloroplasty for refractory gastroparesis. Am Surg. 2015;81(7):738–746(9).
   PubMed Web of Science ®Google Scholar
• Hibbard ML, Dunst CM, Swanström LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J Gastrointest Surg. 2011;15:1513–1519.
   PubMed Web of Science ®Google Scholar
• Abell TL, Van Cutsem E, Abrahamsson H, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion. 2002;66:204–212.
   PubMed Web of Science ®Google Scholar
• Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125:421–428.
   PubMed Web of Science ®Google Scholar
• Humanitarian device exemption for Enterra device. Federal registry. 2000;65:78495–78496.
   Google Scholar
• Gourcerol G, Leblanc I, Leroi AM, et al. Gastric electrical stimulation in medically refractory nausea and vomiting. Eur J Gastroenterol Hepatol. 2007;19:29–35.
   PubMed Web of Science ®Google Scholar
• Anand C, Al-Juburi A, Familoni B, et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. Digestion. 2007;75:83–89.
   PubMed Web of Science ®Google Scholar
• Velanovich V. Quality of life and symptomatic response to gastric neuro- stimulation for gastroparesis. J Gastrointest Surg. 2008;12:1656–1663.
   PubMed Web of Science ®Google Scholar
• McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010;8:947–954.
   PubMed Web of Science ®Google Scholar
• Chu H, Lin Z, Zhong L, et al. A meta-analysis: the treatment of high- frequency gastric electrical stimulation for gastroparesis. J Gastroenterol Hepatol. 2012;27:1017–1026.
   PubMed Web of Science ®Google Scholar
• Brody F, et al. Follow-up after gastric electrical stimulation for gastroparesis. J Am Coll Surg. 2015;220(1):57–63. doi:10.1016/j.jamcollsurg.
   PubMed Web of Science ®Google Scholar
• Grover M, Farrugia G, Lurken MS, et al. Cellular changes in diabetic and idio- pathic gastroparesis. Gastroenterology. 2011;140:1575–85.e8.
   PubMed Web of Science ®Google Scholar
• Mazzone A, Bernard CE, Strege PR, et al. Altered expression of Ano1 variants in human diabetic gastroparesis. J Biol Chem. 2011;286:13393–13403.
   PubMed Web of Science ®Google Scholar
• Grover M, Bernard CE, Pasricha PJ, et al. Clinical-histological associations in gastroparesis: results from the gastroparesis clinical research consortium. Neurogastroenterol Motil. 2012;24:531–9 e249.
   PubMed Web of Science ®Google Scholar
• Horvath VJ, Vittal H, Lorincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of Cajal in murine diabetic gastroparesis. Gastro- Enterology. 2006;130:759–770.
   PubMed Web of Science ®Google Scholar
• Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol. 2003;38:421–430.
   PubMed Web of Science ®Google Scholar
• Gangula PR, Maner WL, Micci MA, et al. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol. 2007;292:G725–33.
   PubMed Web of Science ®Google Scholar
• Gangula PR, Mukhopadhyay S, Ravella K, et al. Tetrahydrobiopterin (BH4), a cofactor for nNOS, restores gastric emptying and nNOS expression in female dia- betic rats. Am J Physiol Gastrointest Liver Physiol. 2010;298:G692–9.
   PubMed Web of Science ®Google Scholar
• Gangula PR, Mukhopadhyay S, Pasricha PJ, et al. Sepiapterin reverses the changes in gastric nNOS dimerization and function in diabetic gastroparesis. Neurogastroenterol Motil. 2010;22:1325–31 e351–2.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Pasricha PJ. Sapropterin improves gastric accommodation and symp- toms in women with diabetic gastroparesis. Neurogastroenterol Motil. 2013;25:36.
   Web of Science ®Google Scholar
• Muller PA, Koscso B, Rajani GM, et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell. 2014;158:300–313.
   PubMed Web of Science ®Google Scholar
• Choi KM, Kashyap PC, Dutta N, et al. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology. 2010;138(7):2399–2409, 2409.e1. doi:10.1053/j.gastro.2010.02.014
   Google Scholar
• Kashyap PC, Choi KM, Dutta N, et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am J Physiol Gastrointest Liver Physiol. 2010;298:G1013–G1019.
   PubMed Web of Science ®Google Scholar
• Bernard CE, Gibbons SJ, Mann IS, et al. Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol Motil. 2014;26:1275–1284.
   PubMed Web of Science ®Google Scholar
• Neshatian L, Gibbons SJ, Farrugia G. Macrophages in diabetic gastroparesis - the missing link? Neurogastroenterol Motil. 2015;27(1):7–18. doi:10.1111/nmo.12418
   PubMed Web of Science ®Google Scholar